通过AKT依赖机制对NSCLC细胞系进行2,3'-二基-5'-甲索西斯蒂尔的抗癌活性:全面的体外和计算分析
Phisit Pouyfung1,2, Nonthalert Lertnitikul3,4, Noriyoshi Ogino5
1Department of Occupational Health and Safety, School of Public Health, Walailak University, Nakhon Si Thammarat 80160, Thailand.
International journal of molecular sciences
|January 28, 2026
概括
一种新型的stilbene化合物对非小细胞肺癌 (NSCLC) 细胞表现出强大的抗癌作用,对正常细胞的毒性降低. 这种针对AKT的药物显示出新肺癌治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 分子药理学分子药理学
- 生物化学 生物化学
背景情况:
- 非小细胞肺癌 (NSCLC) 的耐药性需要新的治疗药物.
- 斯蒂尔因其抗癌性质正在研究中.
研究的目的:
- 评估NSCLC中2,3'-二-5'-甲西斯蒂尔的抗癌活性和选择性.
- 研究该化合物的作用机制,重点关注AKT信号传递.
- 评估该化合物在组合疗法中产生化学敏感性的潜力.
主要方法:
- 在体外测试中使用NSCLC细胞系 (A549,H23,H460) 和正常纤维细胞 (NIH/3T3).
- 细胞活力,增殖,殖民地形成和迁移测定.
- 对于AKT通路蛋白质 (p-AKT,p-GSK3β) 的西部涂抹.
- 分子建模和与西斯普拉丁的组合治疗研究.
主要成果:
- 2,3'-二基-5'-甲氧乙烯对NSCLC细胞具有显著的细胞毒性 (H23/H460的IC50值为23-24μM),对正常纤维细胞的毒性较低 (IC50>100μM).
- 该化合物以剂量依赖的方式抑制了繁殖,殖民地形成和迁移,诱导了亡.
- 机理学研究显示,通过降低p-AKT和p-GSK3β水平,AKT依赖活性.
- 在A549和H460细胞中观察到与思丁的协同作用,但在H23细胞中观察到对抗作用.
结论:
- 2,3′-二-5′-甲氧乙烯是一种选择性AKT向的乙烯,具有对NSCLC有前途的抗癌活性.
- 该化合物表现出取决于环境的化学敏感化作用,表明了组合疗法的潜力.
- 对这种化合物的进一步研究可能会导致NSCLC的新治疗策略.
相关概念视频
01:15Drugs that Stabilize Microtubules
2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:10Drugs that Destabilize Microtubules
3.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K